Skye Bioscience, Inc. Common Stock

Day range

$1.50 – $1.60

Open

$1.55

Prev close

$1.54

Volume

19.49K

Market cap

$6.82M

Shares out

4.43M

P/E

—

P/S

—

P/B

-13.71

P/FCF

—

ROE

10153.2%

ROA

-457.6%

Debt/Equity

-0.29

Div yield

0.00%

As of Oct 23, 2026

• Listing compliance regainedSep 11, 2026

  "The Company received a letter from the Nasdaq Listing Qualifications Department... indicating that the Company's common stock had a closing bid price at or greater than $1.00 per share for the last 10 consecutive business days... and, as a result, the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)... and the matter is now closed."

• Warrant or conversionAug 24, 2026

  the Company agreed to issue to Buyer on the Closing Date a warrant (the "Warrant") to purchase up to a number of shares of Common Stock and/or Non-Voting Common Stock (the "Warrant Shares") equal to $5,000,000 divided by the PIPE Price...The Warrant will be exercisable at any time and from time to time on or after January 1, 2027, and on or prior to 5:00 p.m. (New York City time) on January 1, 2030, at an exercise price per share...equal to the lesser of (1) the PIPE Price and (2) the Market Price as of such date of exercise.

• Listing deficiency noticeAug 19, 2026

  On August 18, 2026, Skye Bioscience, Inc. received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, based on the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, the Company's stockholders' equity was ($497,307), and therefore, the Company was not in compliance with Nasdaq Capital Market's Listing Rule 5550(b)(1), which requires a $2,500,000 minimum stockholders' equity standard.

• Merger agreementAug 14, 2026

  On August 14, 2026, Skye Bioscience, Inc., a Nevada corporation (the "Company"), entered into a transaction agreement ("Transaction Agreement") with Redx Pharma Limited, a private limited company incorporated in England and Wales...the Company will acquire the entire issued and to be issued share capital of Redx pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006.

• Listing deficiency noticeJun 23, 2026

  The Company received a written notification from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, based on the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, the Company's stockholders' equity was $9,011,804, and therefore, the Company was not in compliance with the Nasdaq Global Market's Listing Rule 5450(b)(1)(A), which requires a $10,000,000 minimum stockholders' equity standard.

Days to cover

1.7

Short interest

147.95K

Avg volume

85.21K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
  positiveGlobeNewswire Inc.· Jan 29, 2026
• Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc.(SKYE) Shareholders
  negativeGlobeNewswire Inc.· Jan 15, 2026
• SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
  negativeGlobeNewswire Inc.· Jan 15, 2026
• JYD DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important January 20 Deadline in Securities Class Action - JYD
  negativeGlobeNewswire Inc.· Jan 15, 2026
• Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors
  negativeGlobeNewswire Inc.· Jan 14, 2026